Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bosutinib + Cisplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bosutinib||Bosulif||SKI-606|PF-5208763||ABL Inhibitor (pan) 9 AXL Inhibitor 28 BCR-ABL Inhibitor 28 BTK inhibitor 32 SRC Inhibitor 31 TNK2 Inhibitor 6||Bosulif (bosutinib) inhibits SRC and ABL kinases, and has additional activity against other kinases including AXL, TNK2, BTK, resulting in decreased pathway activation and inhibition of tumor cell proliferation (PMID: 12543790, PMID: 19039322, PMID: 26555154). Bosulif (bosutinib) is FDA approved for use in patients with Ph+ (BCR-ABL) chronic myelogenous leukemia (FDA.gov).|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 7||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SRC positive||biliary tract cancer||sensitive||Bosutinib + Cisplatin||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Bosulif (bosutinib) and Platinol (cisplatin) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).||27196758|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|